报价延迟最少15分钟:2025/07/22 03:05 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
13.62 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.75/-3.22
|
|
企业价值
927.44M
|
| 资产负债 |
|
每股账面净值
5.24
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/22 03:05 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two ormore lines of antihypertensive medication or resistant hypertension, typically including a diuretic. |
